Which companies overlap with Ironshore Pharmaceuticals and Development, Inc's portfolio?

Top competitors by shared drug class: Jiangsu HengRui Medicine Co., Ltd., Melinta Therapeutics, Inc., Veradermics, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ironshore-pharmaceuticals-and-development-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Ironshore Pharmaceuticals and Development, Inc — Portfolio Competitive Intelligence Brief

Ironshore Pharmaceuticals and Development, Inc pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
HLD200	HLD200	phase 3	HDAC inhibitor	Histone deacetylase (HDAC)	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
Melinta Therapeutics, Inc. · 1 shared drug class
Veradermics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ironshore Pharmaceuticals and Development, Inc:

Cite this brief

Drug Landscape (2026). Ironshore Pharmaceuticals and Development, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ironshore-pharmaceuticals-and-development-inc. Accessed 2026-05-16.